Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836163 | 0.80 | POLB (0.41) | POLBHCRTR2ALDH1A1NPSR1CA12 | |
| SCHEMBL4836171 | 0.80 | POLB (0.41) | POLBHCRTR2ALDH1A1NPSR1CA12 | |
| SCHEMBL4836161 | 0.80 | POLB (0.41) | POLBHCRTR2ALDH1A1NPSR1CA12 | |
| SCHEMBL15314096 | 0.72 | ALDH1A1 (0.45) | POLBHCRTR2ALDH1A1LMNANPSR1 | |
| SCHEMBL3228143 | 0.72 | POLB (0.37) | POLBHCRTR2ALDH1A1NPSR1CA12 | |
| SCHEMBL24954674 | 0.72 | — | — | |
| SCHEMBL12265153 | 0.72 | — | — | |
| SCHEMBL12017966 | 0.71 | MMP2 (0.40) | POLBHCRTR2NPSR1CA12CA1 | |
| SCHEMBL12017953 | 0.71 | MMP2 (0.40) | POLBHCRTR2NPSR1CA12CA1 | |
| SCHEMBL5181981 | 0.71 | CA1 (0.40) | POLBHCRTR2ALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557832-B2 | Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110224198-A1 | ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224198-A1 | ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | POLB 3806/4885HCRTR2 250/4885ALDH1A1 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.